BRCA1/2 deficiency has been associated with an immune activation signature in the study by Jiang et al. and through genomic data from The Cancer Genome Atlas (TCGA), genomic and histopathological analyses, Kraya et al. showed that genomic signatures, HR in particular, can predict immunogenicity in BRCA1/2 deficient BC including TNBC, ultimately contributing to the design of appropriate immune therapeutic strategies (Jiang et al., 2016; Kraya et al., 2019). Here, BRCA1 is linked to breast cancer.